Cipla Ltd (CIPLA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Cipla Ltd on NSE and BSE, with an AI summary of each filing.
Appointment of Mr Vikram Janakiraman, as the Global Chief Technical Operating Officer, designated as a Senior Management Personnel of the Company, with effect from 7th December, 2026.
Change in Management · 04 Nov 2026, 8:41 pm
Cipla Appoints Vikram Janakiraman as Global Chief Technical Operating Officer Cipla Limited's Board approved the appointment of Vikram Janakiraman as Global Chief Technical Operating Officer, designated as Senior Management Personnel, effective 7th Dec'26. Janakiraman brings approximately 30 years of experience in consulting leadership and pharma operations. He joins from Boston Consulting Group, where he served as Managing Director and Senior Partner leading Pharma Operations, Industrial Goods, and Manufacturing AI practices. Previously, he managed global manufacturing, supply chain, procurement, and regulatory audits at Glenmark Pharmaceuticals.
Please find enclosed Earnings Call Transcript - Q2FY27
Transcript · 30 Oct 2026, 10:53 pm
In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 29th October, 2026 ....
Others (Uncategorized) · 30 Oct 2026, 2:05 am
Cipla Allots 17,453 Equity Shares Under ESOS and ESAR Schemes Cipla's Operations and Administrative Committee approved the allotment of 17,453 fully paid-up equity shares of INR 2 each on 29th Oct'26, following the exercise of stock options and stock appreciation rights under ESOS 2013-A and Cipla ESAR Scheme 2021. Post-allotment, the company's issued, subscribed, and paid-up equity share capital increased to INR 1,61,57,76,136, representing 80,78,88,068 equity shares of face value INR 2 each.
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the ....
Audio / Video · 28 Oct 2026, 12:20 am
Cipla Releases Audio Recording of Q2 & H1 FY27 Earnings Call Cipla Limited announced that the audio recording of its earnings conference call for the quarter and half-year ended 30th Sep'26, conducted on 27th Oct'26, has been made publicly available on the company's official website in compliance with SEBI LODR Regulations.
Please find intimation in relation to grant of ESOS and ESAR.
Others (Uncategorized) · 27 Oct 2026, 7:25 pm
Cipla Approves Grants Under ESOS 2013-A and ESAR 2021 Schemes Cipla approved the grant of equity-linked incentives under SEBI regulations on 27th Oct'26. The company granted 8,679 stock options under the ESOS 2013-A scheme with a two-year vesting period and an exercise price of INR 2 per option. Additionally, 27,140 Employee Stock Appreciation Rights were granted under the ESAR 2021 scheme at an exercise price of INR 2 per equity share, featuring a three-year graded vesting schedule. Both schemes provide an exercise period of five years from their respective vesting dates.
Please find enclosed the intimation for Appointment of Ms Rashmi Joshi as an additional and independent director of the Company w.e.f. 27th October, 2026 for a period of 5 years.
Change in Management · 27 Oct 2026, 7:22 pm
Cipla Appoints Rashmi Joshi as Independent Director for Five-Year Term Cipla Limited's Board of Directors approved the appointment of Ms Rashmi Joshi as an Additional and Independent Director for a five-year term from 27th Oct'26 to 26th Oct'31, subject to shareholder approval. Joshi brings over three decades of financial and corporate governance experience across FMCG, pharmaceuticals, and lubricants. A qualified CA and CS, she formerly served as Executive Director and CFO of Castrol India Limited and currently holds board positions at multiple firms, including Bharat Forge Limited and GE Vernova T&D India Limited.
Please find enclosed the intimation for appointment of Ms Rashmi Joshi as an additional and independent director of the company w.e.f. 27th October, 2026 for a period of 5 years.
Outcome · 27 Oct 2026, 7:18 pm
Cipla Appoints Rashmi Joshi as Independent Director for Five-Year Term Cipla Limited's Board of Directors approved the appointment of Ms Rashmi Joshi as an additional and independent director for a five-year term from 27th Oct'26 to 26th Oct'31, subject to shareholder approval. A qualified Chartered Accountant and Company Secretary with over 30 years of corporate governance and finance experience, Joshi previously served as Executive Director and CFO of Castrol India. Her appointment brings cross-industry leadership across FMCG, consumer durables, lubricants, and pharmaceuticals to strengthen board governance.
Please find enclosed investor presentation.
Investor Presentation · 27 Oct 2026, 7:10 pm
Cipla Reports Q2FY27 Financial Results Cipla reported consolidated revenue from operations of INR 7,404 Cr for Q2FY27, down from INR 7,589 Cr in Q2FY26. EBITDA stood at INR 1,388 Cr with an 18.7% margin, compared to INR 1,895 Cr (25.0% margin) YoY, while PAT declined to INR 878 Cr (11.9% margin) from INR 1,351 Cr. One India delivered record quarterly revenue of INR 3,516 Cr, up 12% YoY. North America contributed $172 Mn, bolstered by US FDA approval for generic Advair Diskus across all strengths. R&D spending reached INR 423 Cr (5.7% of revenue).
Please find enclosed press release for Q2FY27 financial results.
Press Release · 27 Oct 2026, 7:06 pm
Cipla Reports Q2FY27 Results: India Grows 12% YoY While Margins Contract Cipla reported Q2FY27 consolidated revenue of INR 7,404 Cr, down 2% YoY but up 4% QoQ. EBITDA stood at INR 1,388 Cr with margins at 18.7% (expanding 200 bps QoQ but declining from 25.0% in Q2FY26), while PAT reached INR 878 Cr. One-India revenue rose 12% YoY to INR 3,516 Cr, whereas North America revenue dropped 19% YoY to INR 1,643 Cr ($172 Mn). Balance sheet remained robust with a net cash position of INR 9,823 Cr and R&D spending at 5.7% of sales.
Cipla Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 27 Oct 2026, 7:01 pm
Cipla Reports Q2 Results for Period Ended 30th Sep'26 Cipla reported consolidated revenue from operations of ₹7,403.93 crore for the quarter ended 30th Sep'26, down 2.44% YoY from ₹7,589.44 crore but up 4.00% QoQ from ₹7,119.28 crore. Consolidated net profit attributable to owners fell 35.05% YoY to ₹877.54 crore compared to ₹1,351.17 crore in the prior-year period, while rising 11.21% QoQ. Basic EPS stood at ₹10.86 versus ₹16.73 YoY. For H1 ended 30th Sep'26, consolidated revenue was ₹14,523.21 crore with PAT of ₹1,666.59 crore. Ongoing NPPA DPCO litigations involve ₹2,011 crore with no provisions made.
Please find enclosed the financial results for the quarter and half year ended 30th September, 2026.
Financial Result · 27 Oct 2026, 6:52 pm
Cipla Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 7,404 (-2.4% YoY | +4.0% QoQ) ■ EBITDA: 1,388 (-26.8% YoY | +16.4% QoQ) ■ EBITDA Margin (%): 18.7 (-622 bps YoY | +200 bps QoQ) ■ PAT: 878 (-35.1% YoY | +11.2% QoQ) ■ EPS (INR): 10.9 (-35.1% YoY | +11.2% QoQ)
Please find enclosed disclosure.
Others (Uncategorized) · 23 Oct 2026, 2:32 pm
Cipla Subsidiary InvaGen Receives Zero USFDA Observations for New York Facility The USFDA conducted a routine current Good Manufacturing Practices (cGMP) inspection at the Hauppauge, Long Island, New York facility of Cipla's wholly owned subsidiary, InvaGen Pharmaceuticals Inc., from 19th Oct'26 to 22nd Oct'26. The inspection concluded successfully with zero Form 483 observations, confirming full regulatory compliance for the manufacturing site.
Please find enclosed intimation for Earnings Conference Call.
Intimation · 27 Oct 2026, 4:00 pm
Cipla Schedules Q2FY27 Earnings Conference Call for 27th Oct'26 Cipla Limited will announce its unaudited financial results for Q2FY27 on 27th Oct'26. Following the result announcement, company leadership will host an earnings conference call at 16:00 IST (18:30 SST/HKT, 10:30 GMT, 06:30 US ET) to discuss financial performance and address investor queries. Primary access numbers for the call are +91 22 6280 1562 and +91 22 7115 8387, alongside international toll-free options. The call transcript will subsequently be made available on the company’s website.
CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....
Intimation · 27 Oct 2026, 5:30 am
Cipla Board to Consider Q2FY27 Financial Results on 27th Oct'26 Cipla Limited's Board of Directors is scheduled to meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. Consequently, the trading window for dealing in company securities will remain closed from 1st Oct'26 to 29th Oct'26 (both days inclusive) in compliance with insider trading regulations.
Cipla limited has informed the Exchange about Board Meeting to be held on 27th October, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half-year ended 30th September, 2026.
Intimation · 27 Oct 2026, 5:30 am
In terms of Regulation 30 of SEBI (LODR) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 24th September, 2026 has allotted 12,168 ....
Others (Uncategorized) · 25 Sept 2026, 12:37 am
Cipla Allots 12,168 Equity Shares Under ESOS and ESAR Schemes On 24th Sep'26, Cipla Limited's Operations and Administrative Committee approved the allotment of 12,168 fully paid-up equity shares of INR 2 face value pursuant to the exercise of employee stock options and stock appreciation rights under ESOS 2013-A and ESAR Scheme 2021. Following this allotment, the company's issued, subscribed, and paid-up equity share capital expanded to INR 1,61,57,41,230, comprising 80,78,70,615 equity shares of INR 2 each.
Please find enclosed disclosure relating to the Change in SMP.
Change in Management · 23 Sept 2026, 4:26 am
Cipla Announces Senior Management Transition in Global Supply Chain Leadership Cipla Limited announced that Mr Venkata Sai Mungara, Global Head Supply Chain, will transition to the role of Chief of Manufacturing and Supply Chain Operations at Cipla USA Inc., a wholly owned subsidiary, effective 1st Oct'26. Consequently, Mr Mungara will cease to be designated as Senior Management Personnel of the parent company starting from the same date.
Please find enclosed disclosure on ESG Rating.
Others (Uncategorized) · 18 Sept 2026, 11:02 pm
Cipla Assigned ESG Rating of 68 by SEBI-Registered Niche Cipla has been assigned an Environmental, Social, and Governance (ESG) rating of 68 by SEBI-registered ESG Rating Provider Niche Ninety Nine Capability and Certifications. The assignment was communicated directly by Niche to the NSE on 11th Sep'26 and to the BSE on 17th Sep'26 without prior direct communication to Cipla. The company became aware of the rating via a BSE alert disseminated on 17th Sep'26 at 18:50 IST, subsequently notifying stock exchanges under Regulation 30 of SEBI LODR Regulations.
Please find enclosed press release titled ''Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US''
Press Release · 04 Sept 2026, 1:36 am
Cipla Secures Exclusive US Licensing for Keytruda Biosimilar from Qilu Pharmaceutical On 3rd Sep'26, Cipla announced an exclusive US licensing and supply partnership with Qilu Pharmaceutical for QL2107, a biosimilar to Keytruda (pembrolizumab). Under the agreement, Qilu assumes responsibility for development, regulatory registration, and manufacturing supply, while Cipla USA secures commercialization rights. This partnership enables Cipla to leverage its existing US commercial infrastructure to expand its oncology-focused biosimilar portfolio. The strategic addition of this asset significantly strengthens Cipla's US pipeline, positioning the company to capture share in a high-value market upon regulatory approval.
Please find enclosed disclosure
Others (Uncategorized) · 03 Sept 2026, 10:13 pm
NCLT Dispenses Shareholder Meetings for Cipla's Absorption of Inzpera Healthsciences On 3rd Sep'26, Cipla announced that the NCLT (Mumbai) dispensed with convening meetings for equity shareholders and unsecured creditors regarding the absorption of Inzpera Healthsciences. The NCLT order, dated 18th Aug'26, acknowledges Cipla has no secured creditors. Stakeholders are granted a 30-day window from notice receipt to file representations with the NCLT. A lack of response within this timeframe constitutes presumed consent to the proposed amalgamation. This procedural exemption effectively streamlines Cipla's corporate restructuring and integration timeline.
Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"
Press Release · 31 Aug 2026, 9:12 pm
Cipla In-Licenses HER2 Bispecific ADC from SBP Group for Emerging Markets Cipla has signed an exclusive licensing and supply agreement with SBP Group's subsidiary, CTTQ, for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific antibody-drug conjugate. The deal, announced on 31st Aug'26, grants Cipla exclusive rights to develop and commercialize the oncology asset in India, South Africa, and five other emerging markets. TQB2102 shows encouraging potential in HER2-low advanced breast cancer. Cipla will manage local clinical development and commercialization, while CTTQ will handle manufacturing and supply, strengthening Cipla's oncology portfolio.
Please find enclosed disclosure.
Others (Uncategorized) · 29 Aug 2026, 2:47 am
Cipla: USFDA Classifies InvaGen Facility Inspection as Voluntary Action Indicated (VAI) Cipla announced on 28th Aug'26 that the USFDA has classified the inspection of its InvaGen Pharmaceuticals facility as Voluntary Action Indicated (VAI). The inspection of the Unit 3 manufacturing facility in Central Islip, New York, occurred from 13th Jul'26 to 17th Jul'26. The VAI classification indicates that although objectionable conditions or practices were found, the agency will not take or recommend regulatory action. This outcome mitigates a key regulatory overhang for the US subsidiary.
Please find enclosed disclosure.
Others (Uncategorized) · 28 Aug 2026, 1:45 am
Cipla Simplifies Group Structure with Internal Stake Transfer On 27 Aug'26, Cipla announced a group restructuring to simplify its corporate structure. Aspergen Limited, India, a 60:40 JV between Cipla and Kemwell Biopharma, has acquired a 100% stake in Aspergen Inc., USA. Previously, Aspergen Inc. was a step-down subsidiary held 60% by Cipla (EU) Limited and 40% by Kemwell Biopharma UK. Post-restructuring, Aspergen Inc. becomes a wholly-owned subsidiary of Aspergen Limited. Cipla confirmed there is no change to its ultimate economic interest in Aspergen Inc., USA.
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / ....
Intimation · 27 Aug 2026, 8:18 pm
Cipla Announces September '26 Investor and Analyst Meetings Cipla has scheduled in-person meetings with analysts and institutional investors. The company will participate in the Jefferies India Forum Conference in Gurgaon on 17th Sep'26. This will be followed by the Kotak Healthcare Conference in Mumbai on 18th Sep'26. The schedule, announced on 27th Aug'26, is subject to change based on unforeseen circumstances.